Media OutReach
Immuno Cure Kicks off Phase I Clinical Study of Therapeutic DNA Vaccine for HIV in Hong Kong
As a lead candidate under Immuno Cure’s patented “PD-1-Enhanced DNA Vaccine Technology Platform”, ICVAX aims to achieve sustained, immune-mediated HIV-1 virological control without the need of antiretroviral therapy. Following the successful first-in-human ICVAX Phase I clinical trial in Shenzhen that showed exceptional safety and immunogenicity profiles, this clinical study will explore the safety and immunogenicity of ICVAX in HIV-infected volunteers in Hong Kong, to be administered by three distinct delivery systems. This comparative approach will provide essential data on the optimal delivery method for ICVAX, and hence potentially identifying the most effective, patient-friendly and scalable option for enhancing immunotherapeutic responses in people living with HIV.
The clinical study will be conducted at Prince of Wales Hospital and will be led by Dr Grace LUI, Head of the Division of Infectious Diseases at CUHK Medicine’s Department of Medicine and Therapeutics, as the Principal Investigator. This is a randomized clinical study to evaluate the immunogenicity and safety of ICVAX in a total of 22 HIV-infected volunteers using three delivery systems: Teresa-EPT-1 electroporation device, PharmaJet’s Tropis, a WHO pre-qualified needle-free injection system, and PapiVax’s TriGrid EP device.
This study has been granted ΗΚ$4.2 million funding under the Public Sector Trial Scheme of the Innovation and Technology Fund of the HKSAR Government (project reference number: UTT/002/23GM). Professor Zhiwei CHEN, Director of the HKU AIDS Institute and Principal Scientific Advisor of Immuno Cure, serves as the Project Coordinator for this funding. This study is also partially supported by Theme-based Research Scheme (TRS) of the Research Grants Council under the University Grants Committee of the Education Bureau (project reference number: T11-702/24-N).
“This Phase I clinical study is an important landmark, being the first evaluation of ICVAX in Hong Kong volunteers and incorporating multiple innovative delivery technologies,” said Dr Grace LUI. “By testing these devices, we aim to optimize safety, immunogenicity, and patient experience for this promising HIV therapeutic DNA vaccine candidate.”
“ICVAX is built on the innovative PD-1-Enhanced DNA vaccine technology invented and developed locally at the HKU,” said Professor Zhiwei CHEN. “This study will help optimize delivery of ICVAX, paving the way for broader international deployment.”
“The launch of this clinical study is a major milestone of vaccine development for Immuno Cure,” said Dr Xia JIN, CEO of Immuno Cure. “By testing ICVAX for the first time in Hong Kong and comparing three innovative delivery devices this study not only advances our understanding of the performance of our DNA medicines, but also significantly supports the global commercialization of ICVAX and our other DNA medicines. Immuno Cure is committed to leading innovation in immunotherapy to combat infectious diseases and cancers.”
Hashtag: #ImmunoCure
The issuer is solely responsible for the content of this announcement.
About Immuno Cure
Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine Platform and Anti-Δ42PD1 Antibody Platform
To learn more about Immuno Cure, please visit http://www.immunocure.hk.
About CUHK Medicine
Established in 1981, CU Medicine has achieved international recognition in teaching, research, and clinical practice and is the youngest medical school ranked among the world’s top 25 in many global rankings. In the “Best Global Universities Subject Rankings 2025-26” by U.S. News and World Report, its “Gastroenterology and Hepatology”, “Endocrinology and Metabolism” and “Clinical Medicine” programmes rank 1st in Asia, while Gastroenterology and Hepatology claims 2nd globally.
The Faculty comprises 14 clinical departments and five schools, delivering a world-class environment for teaching and research with a strong emphasis on interdisciplinary, interprofessional, and international collaboration. To date, it has cultivated over 6,000 medical graduates who are making an impact across local and global healthcare systems. The Faculty is dedicated to driving innovation by translating groundbreaking research into real-world clinical applications. Its contributions have reshaped medicine — evidenced by the filing of 3,000 patents, strategic patent acquisitions, and the establishment of more than 20 start-ups. Its pioneering research has not only rewritten international clinical guidelines but also revolutionised the prevention, diagnosis, and treatment of numerous diseases.
To learn more about CU Medicine, please visit http://www.med.cuhk.edu.hk.
About HKU AIDS Institute
HKU AIDS Institute was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Currently, the Institute is leading the Hong Kong Theme-based Research Scheme entitled “Potentiating Host Immunity for HIV-1 Functional Cure”.
To learn more about HKU and AIDS Institute of HKU, please visit https://www.hku.hk/ and https://www.med.hku.hk/aidsinst/.
About BAY TRIAL
BAY TRIAL is a key initiative in implementing the “Notice of the State Council on Issuing the Development Plan for the Shenzhen Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone” (State Council [2023] No. 12). It serves as strong support for Shenzhen’s development as an international science and technology innovation centre and for promoting the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Located in the Hetao Shenzhen-Hong Kong Cooperation Zone, BAY TRIAL leverages the zone’s unique geographical and policy advantages to integrate clinical trial innovation resources across the GBA, deepen Shenzhen-Hong Kong science and technology collaboration, and establish a one-stop clinical trial platform.
To learn more about BAY TRIAL, please visit: https://baytrial.smart.org.cn/about/index.html
Media OutReach
NIA Spotlights Thailand’s Wellness Boom as Global Consumers Spend Boundlessly on Longevity
- Deep dive into the DNA of Thailand’s wellness giants—BDMS Wellness Clinic and Chiva-Som—and their strategic blueprints to transform the kingdom into the ultimate global wellness destination.
BANGKOK, THAILAND – Media OutReach Newswire – 20 July 2026 – In the modern era, “good health” has redefined the meaning of true wealth. Consumers worldwide are now heavily investing in innovations that promote longevity and extend healthspan—the period of life spent in good health. Even amid economic uncertainty, health and well-being remain top priorities for consumers. This behavioral shift helping drive the global wellness economy to a reached USD 6.8 trillion in 2024, representing a 7.9% growth from the previous year. Furthermore, the Global Wellness Institute (GWI) projects the market to surge to USD 9.8 trillion by 2029, maintaining an average annual growth rate of 7.6%. Driven by this exponential growth, nations worldwide, including Thailand, are aggressively developing wellness services and innovations to serve as a “New Growth Engine” and a key indicator of long-term national competitiveness.
Where Does Thailand Stand in the Global Health & Wellness Industry?
When evaluating Thailand’s potential, Thailand ranks among the world’s leading healthcare destinations. According to the Numbeo Health Care Index 2026, Thailand’s healthcare system is ranked 8th globally, making it the sole ASEAN nation to secure a spot in the Top 10. Focusing specifically on the health and wellness sector, Thailand achieved the highest growth rate globally in 2023, with the market value soaring past USD 40 billion—a remarkable 28.4% increase. The “Wellness Tourism” segment alone skyrocketed by 36.4%, outperforming the global average by threefold.
These figures reflect much more than financial profits; they underscore Thailand’s robust readiness and distinct advantages. The country boasts world-class medical infrastructure, accredited hospitals, highly skilled medical professionals, reasonable treatment costs, and an established reputation as a top wellness destination. Additionally, Thailand possesses unique cultural assets—such as traditional Thai herbs, Thai massage, healthy cuisine, and medical tourism—that can be strategically leveraged into a high-value economy.
Driving a High-Income Economy with Deep Tech in the Wellness Market
Prof. Dr. Yodchanan Wongsawat, Deputy Prime Minister and Minister of Higher Education, Science, Research and Innovation (MHESI), announced a strategic vision to transform Thailand’s wellness industry from traditional services into a high-value, globally competitive innovation sector. The strategy aims to unlock the potential of Thai culture, local wisdom, and rich biodiversity by implementing modern science and technology to establish evidence-based efficacy. Furthermore, cutting-edge innovations such as Health Tech, Artificial Intelligence (AI), and Machine Learning (ML) will be deployed to analyze deep health data. Equipping the sector with Deep Tech will significantly elevate international credibility.
Prof. Dr. Yodchanan emphasized: “MHESI is fully prepared to act as a vital gear in mitigating R&D investment risks for the private sector through an end-to-end support system. We aim to accelerate the commercialization of Thai innovations by systematically connecting the innovation ecosystem. This includes matchmaking entrepreneurs, startups, researchers, and universities, alongside injecting comprehensive financial and resource support. Our assistance spans R&D grants, advanced laboratory access, clinical trials, global production standard upgrades, and intellectual property protection. Collectively, these mechanisms will propel wellness into a New Growth Engine, boosting national competitiveness and establishing Thailand as a true global wellness hub.”
NIA’s Four Strategic Pillars to Propel the Thai Wellness Economy Globally
Dr. Krithpaka Boonfueng, Executive Director of the National Innovation Agency (NIA), stated that driving the wellness industry sustainably cannot be achieved by the private sector alone. It requires cross-sector collaboration to foster an innovation ecosystem conducive to research, technological development, standard testing, and global market expansion. The NIA has continuously supported entrepreneurs in health, wellness, and medical technology through capacity-building initiatives like the Wellness Academy, startup incubation, university network integration, and innovation competitions to translate ideas into market-ready businesses.
The NIA prioritizes data, research, and scientific evidence to build trust and add value to Thai wellness products and services. Simultaneously, the agency connects entrepreneurs to vital resources and innovation networks to stimulate the healthcare economy, creating jobs and new revenue streams through four key strategies:
- Connecting Innovative Businesses: Fostering synergies across the ecosystem.
- Upgrading Wellness Establishments and Labor Skills: Elevating service standards and workforce capabilities to international levels.
- Driving Progress via Thailand Innovation Hubs: Utilizing regional hubs to stimulate localized innovation.
- Scaling Up and Building International Recognition: Enhancing global awareness of Thai wellness as credible, safe, verifiable, and uniquely high-value.
The NIA’s ultimate goal is not merely to create new innovative businesses, but to build a sustainable ecosystem that empowers Thai entrepreneurs to grow robustly and integrate seamlessly into the global health and wellness supply chain.
BDMS Champions “Healthspan” and Preventive Medicine to Secure a Competitive Edge
As longevity becomes a primary aspiration for the global population, BDMS Wellness Clinic—a premier wellness leader in Thailand—is accelerating the preventive healthcare industry. By utilizing health science and personalized medicine, the clinic designs deep-level bodily care to firmly establish Thailand as a pioneer in modern health trends.
Dr. Tanupol Virunhagarun, Chief Executive Officer of BDMS Wellness Group, Bangkok Dusit Medical Services Public Company Limited (BDMS), highlighted that transitioning from treating illnesses to preventing them is an undeniable global megatrend. This aligns with World Health Organization (WHO) data indicating that every 1 Baht invested in wellness yields up to a 35-fold return by reducing public healthcare expenditures and enhancing citizen quality of life. This expertise has positioned BDMS Wellness Clinic as a major private-sector anchor, attracting high-spending global consumers to Thailand through its concept of “Scientific Wellness.” This approach features evidence-based healthcare, ranging from advanced genetic testing and personalized nutrition and vitamin formulations to blending modern medical innovations with traditional Thai medicine for verifiable results. Upgrading these standards shifts Thailand’s image from a leisure destination to a highly credible, advanced medical hub, serving as a crucial mechanism in partnering with the government to promote the nation as “Wellness Hub Thailand, The Land of Life” and a top-of-mind Global Wellness Destination.
Chiva-Som Showcases the “Thai Spirit” to Redefine the Health Economy
Complementing advanced medical dimensions, Thailand possesses iconic brands in health tourism marketing, such as Chiva-Som—the country’s first wellness resort and a pioneer in Asia. Spanning over three decades, Chiva-Som evolved from a modest beachfront holiday home in Hua Hin into one of the world’s top wellness resorts, capturing the loyalty of high-net-worth consumers from the West. What sets Chiva-Som apart is not just its world-class international treatments, but the “Thai spirit of hospitality”—characterized by humility, gentleness, and sincerity—seamlessly integrated with a profound understanding of holistic wellness.
Drawing from this tangible success, Mr. Krod Rojanastien, Consultant to President of Chiva-Som International Health Resort Co., Ltd., shared a pivotal insight: In a digital era where people face chronic stress and burnout, wellness has become mainstream. Thailand holds a distinct competitive advantage through its innate service spirit, gentle culture, and centuries-old traditional Thai medical wisdom. Moving forward, the priority must be backing this traditional wisdom with scientific research to secure international trust. Thailand’s future marketing goal must transcend being a temporary vacation spot; it must elevate into a global “Sanctuary” where people intentionally travel to restore their body, mind, and overall quality of life.
When science, technology, innovation, and Thai wisdom are systematically woven together, the wellness economy will transform from a mere service sector into a powerful economic engine. It will lead Thailand toward becoming a definitive Global Wellness Destination, generating economic wealth and holistic well-being simultaneously.
Hashtag: #NIA #NationalInnovationAgency
https://www.nia.or.th/The issuer is solely responsible for the content of this announcement.
Media OutReach
International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) gathers global experts in Chinese Medicine
Concurrent Food Expo features “Multi-Facets of Chinese Medicine” exhibition
HONG KONG SAR – Media OutReach Newswire – 20 July 2026 – The 25th International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM), organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, will be held from 13 to 15 August at the Hong Kong Convention and Exhibition Centre (HKCEC), offering industry professionals the latest insights into Chinese medicine. This year’s conference is funded by the Chinese Medicine Development Fund of the Government of the Hong Kong Special Administrative Region. It is dedicated to strengthening the ties between Hong Kong’s Chinese medicine industry and the international market, while promoting Hong Kong’s leading role in the global field of Chinese medicine.
Register for the conference to stay updated with the latest industry information on Chinese medicine: https://tinyurl.com/tmvryr38
Aligning with the strategic Blueprint with a focus on “Bringing In and Going Global”
The Chinese Medicine Development Blueprint of Hong Kong (the Blueprint) released in 2025 positions Hong Kong as a bridgehead for the global internationalisation of Chinese medicine and a key highland within the national framework for Chinese medicine development. To actively support the strategic direction of the Blueprint, this year’s conference adopts the theme Clinical Translation, Regulatory Policies and Global Innovative Pathways of Traditional Medicine, focusing on two core elements: bringing in and going global. It introduces Hong Kong’s Chinese medicine regulations and resource support to participants from Chinese Mainland and overseas, while inviting overseas regulatory authorities to share their local traditional medicine regulations. This year, some 30 experts and scholars from Hong Kong, Chinese Mainland, and overseas have been invited to comprehensively explore the latest research and development trends, regulatory interpretations, and success cases in Chinese medicine.
The three-day conference is divided into five major thematic sessions, covering policy blueprints, international regulations, clinical research, success case sharing, and talent cultivation:
To help enterprises from Chinese Mainland and abroad understand Hong Kong’s Chinese medicine regulation and support, Dr. Vincent Chung Chi-ho, Commissioner for Chinese Medicine Development, Chinese Medicine Unit, Health Bureau, will elaborate on the Blueprint, while Law Kwok-wai, Robert, Chief Pharmacist (Chinese Medicine), Chinese Medicine Regulatory Office, Department of Health, Dr. Yeung Kin Wai, Senior Chemist, Government Chinese Medicines Testing Institute, Department of Health, and Prof. Bian Zhaoxiang, Hospital Chief Executive, The Chinese Medicine Hospital of Hong Kong (CMHHK) , will share in-depth insights into the latest progress in Chinese medicine regulation, quality standards testing, and clinical practice and research at the Chinese Medicine Hospital. Furthermore, Arnold Lau, Associate Director-General, Invest Hong Kong, Dr. William Cheung, Deputy Chief Manager (Life and Health Technology), Office for Attracting Strategic Enterprises (OASES), Angela Yu, Deputy Head of Health Tech and TCM, Hong Kong Productivity Council and Wing Chu, Deputy Director of Research, HKTDC, will participate in a panel discussion to analyse the Hong Kong government’s resource support for the development of Chinese medicine.
To provide attendees with a comprehensive analysis of market trends, Prof. Zheng Linyun, Executive Vice President of the Shanghai Academy of International Standardization of Traditional Chinese Medicine, will share reflections and prospects on the transformation of ISO/TC249. Furthermore, Prof. Taruna Ikrar, Chairperson of the Indonesian Food and Drug Authority (BPOM), Indonesia, Nurul Anisah Binti Shahri from National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health, Malaysia and Thawatchai Nakkaratniyom, Senior Professional Level Pharmacist, Head of Pre-marketing Control Group, Herbal Products Division at Thai Food and Drug Administration, Ministry of Public Health, Thailand will jointly analyse the regulations and standards of the Southeast Asian market.
Scientific and clinical experts will share the latest progress in the scientific research and clinical application of Chinese medicine, as well as experiences regarding the R&D application and clinical efficacy of hospital-made Chinese medicine preparations. Prof. Zhang Zhongde, Deputy President of Guangzhou University of Chinese Medicine & President of Guangdong Provincial Hospital of Chinese Medicine will share Chinese Mainland’s practices in the research and development of Chinese medicine. Prof. Lee Sanghoon, Dean, International Education Institute of Korean Medicine, Kyung Hee University will discuss the development of new natural product drugs in Korea. Prof. Pei Xiaohua, Dean of Changping Hospital Affiliated to Beijing University of Chinese Medicine and Director of the Institute of Traditional Chinese Surgery will discuss clinical needs in developing new Chinese herbal medicines for TCM-advantageous breast diseases. Locally, Prof. Zhang Ge from Hong Kong Baptist University will present innovative achievements in utilising traditional Chinese medicine to drive target discovery for triple-negative breast cancer, while Prof. Xian Yanfang Lisa, Assistant Professor, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong will share pre-clinical and clinical studies of novel Chinese medicine formula for treating gout.
Focusing on successful industry practices, ICMCM provides an interactive platform for the industry, helping to ensure the continuous development and growth of the traditional Chinese medicine sector. Yan Han, Chairman, Beijing Tong Ren Tang Chinese Medicine Company Limited will share the cultural heritage and internationalised development of Chinese medicine, and Dr. Celine Cheng, Chief Compliance & Technology Officer of Jacobson Pharma Corporation Limited will share GMP applications in the industry. Several professors from Chinese Mainland, Australia, Canada, Macao, and Singapore—including Prof. Li Min, Dean and Chair Professor, School of Chinese Medicine, Hong Kong Baptist University; Prof. Xu Hongxi, Chairman, Belt and Road Alliance for Traditional Medicine, Honorary Dean & Distinguished Professor, Shanghai University of Traditional Chinese Medicine; Prof. Zhu Xiaoshu, Co-Director, Australia-China Chinese Medicine Centre, Western Sydney University, Australia; and Prof. Linda Zhong, Director, Biomedical Sciences and Chinese Medicine, School of Biological Sciences, Nanyang Technological University, Singapore —will explore training models for Chinese medicine talent at home and abroad, alongside market demands for Chinese medicine products in potential markets.
The Symposium will be held on the morning of 15 August. This year, it is jointly organized by eight institutions, including four Hong Kong universities—The Chinese University of Hong Kong, The University of Hong Kong, Hong Kong Baptist University, and The Hong Kong University of Science and Technology—alongside Nanyang Technological University in Singapore, the University of Macau, Shanghai University of Traditional Chinese Medicine, and Guangzhou University of Chinese Medicine. The Symposium will kick off with Vincent & Lily Woo Fellowship in Memory of Dr Albert Wong endowed by Vincent & Lily Woo Foundation Award Presentation Ceremony, hosted by the Modernized Chinese Medicine International Foundation. This year’s Symposium will feature nearly 100 research presentations, including oral research presentations by 10 postgraduate students from Hong Kong, Chinese Mainland, Australia, Singapore, South Korea, Vietnam, and Serbia, and nearly 90 poster displays. The judging panel will select 10 winners for the Tianjiang Cup Li Shizhen Youth Outstanding Thesis Award. The Symposium not only provides a platform for postgraduate students in Chinese medicine to share their research progress and achievements but also promotes student collaboration and exchange, laying an important cornerstone for cultivating a new generation of scientific research professionals and driving the development of Chinese medicine.
This year’s conference continues to operate under the hybrid model, with simultaneous interpretation in both English and Putonghua offered to enable wider industry participation.
In addition to the professional conference tailored for industry practitioners, ICMCM is committed to promoting the popularisation and implementation of Chinese medicine in the community through a public education display area titled “Multi-Facets of Chinese Medicine” at the concurrent Food Expo. In response to the directives of the Blueprint, this interactive and educational display aims to significantly enhance the public’s correct understanding of and confidence in Chinese medicine.
The design of the exhibition is closely aligned with the development direction set out in the Blueprint, providing a comprehensive overview of the new chapter in Hong Kong’s Chinese medicine sector. It covers four main themes including the latest development trends of Chinese medicine in Hong Kong, the service features of the Chinese Medicine Hospital of Hong Kong, the Hospital Authority’s Chinese medicine outpatient services, Chinese medicine regulation framework and Chinese medicine practitioner registration system, alongside knowledge on Chinese medicine wellness practices.
A half-day ICMCM Public Forum will be held on Saturday, 15, August 2026, to promote the advantages of Chinese medicine services, interesting Chinese medicine wellness tips and preventive healthcare. By running industry conferences alongside public exhibitions and forums in parallel, the event aims, on the one hand, to foster academic and industrial innovation exchanges among global Chinese medicine experts, and on the other, to embed Chinese medicine culture deeply into the daily lives of the public, thereby jointly promoting Hong Kong’s development as an international centre for Chinese medicine.
Conference programme: icmcm.hktdc.com/pdf/2026/programme.pdf
Website: hktdc.com/icmcm
Concurrent Exhibitions:
HKTDC Food Expo PRO foodexpopro.hktdc.com
HKTDC Hong Kong International Tea Fair hkteafair.hktdc.com
HKTDC Food Expo hkfoodexpo.hktdc.com
HKTDC Beauty & Wellness Expo hkbeautyexpo.hktdc.com
HKTDC Home Delights Expo homedelights.hktdc.com
Hashtag: #HKTDC #ICMCM
The issuer is solely responsible for the content of this announcement.
Media OutReach
Imperial Harvest Unveils US$1.888 Million Mahjong Set in Singapore, With All Proceeds Pledged to Childhood Brain Cancer Research
For generations, mahjong has been far more than a pastime. Rich in symbolism, strategy and tradition, the centuries-old game has long brought families and friends together around a table, and today it is enjoying a global resurgence, winning new audiences across the United States and beyond.
Against this backdrop, the one-of-one creation brings together exceptional materials, artisanal craftsmanship and Imperial Feng Shui principles into a collector’s piece that channels cultural heritage into meaningful change.
Turning Prosperity Into Hope for Children
Diffuse Intrinsic Pontine Glioma (DIPG) is a rare and aggressive brain tumour that primarily affects children between the ages of five and 11, and has long been considered incurable. In 2024, doctors reported the world’s first case of a child effectively cured of DIPG, renewing global momentum in the field — yet research into the disease remains critically underfunded.
All proceeds from the sale of the mahjong set will be donated to DIPG Foundation Singapore, Singapore’s first foundation dedicated to advancing research into DIPG and other paediatric brain cancers. Founded by families who each experienced the loss of a child to the disease, the foundation supports research, advocates for greater access to innovative therapies and clinical trials, and provides resources for affected children and their families.
For Grand Master David Goh, founder of Imperial Harvest, donating the proceeds reflects a belief that prosperity carries its greatest meaning when it can be shared. The mahjong set celebrates abundance through symbolism and craftsmanship while channelling that value into research that brings hope to affected children and their families.
A Fading Craft, Reimagined
The set arrives at a time when the traditional art of mahjong tile carving is fading worldwide, lending its craftsmanship a significance beyond luxury alone. At the heart of the set are 156 playing tiles, including Animal, Fei and Joker tiles, individually crafted in untreated Burmese Grade A Black Jadeite. Revered for its rarity and cultural significance, the stone has long been associated with protection, resilience and prosperity, with every tile retaining its natural individuality.
The tiles are housed in a bespoke trunk wrapped in exceptionally rare Himalayan Niloticus crocodile leather, prized for its naturally occurring gradient reminiscent of snow-capped mountain peaks and sourced from a tannery that supplies some of the world’s most prestigious luxury maisons. Inside, aerospace-grade Alcantara — the same premium material found in the interiors of Ferrari and Lamborghini supercars — creates a soft, durable lining that protects every tile.
Where Feng Shui Meets Design
Guided by third-generation feng shui master Grand Master David Goh, every detail has been considered not only for its visual appeal but also for its symbolic significance, resulting in a collector’s piece that seeks to harmonise Heaven, Earth and humanity.
The conventional Singapore animal tiles have been replaced by the Four Celestial Guardians — the Azure Dragon, Vermilion Phoenix, White Tiger and Black Tortoise — mythical creatures deeply rooted in Chinese cosmology that traditionally represent protection, balance and harmony. Likewise, the flower tiles have been redesigned to depict four auspicious creatures: the bat, deer, crane and magpie, collectively symbolising fortune, prosperity, longevity and happiness.
Even one of mahjong’s most recognisable tiles, the Seven Dots, has been reimagined. Instead of following its conventional arrangement, the seven circles are positioned according to the “Seven Star Lighting” formation, an Imperial Feng Shui configuration believed to represent stability, clarity and strategic balance. The Character suit, meanwhile, features English transliterations such as “Yi Wan”, “Er Wan” and “San Wan”, making the set accessible to an international audience while preserving its cultural identity.
As Grand Master David Goh describes it, the set is “far beyond a Mahjong set. Every detail has been calibrated to harmonise Heaven, Earth and Man, ensuring that its owner engages not just in a game, but in a field of aligned opportunity, protection and infinite prosperity.”
A New Definition of Luxury
Whether viewed as a collector’s piece, a work of design or cultural heritage, the Imperial Feng Shui Mahjong Set occupies a category of its own — a reminder that the greatest luxury may ultimately be the opportunity to create meaningful change. It is a philosophy that Imperial Harvest carries through its bespoke Feng Shui consultation services in Singapore, where prosperity is understood as something to be built, and shared.
Hashtag: #ImperialHarvest #GrandMasterDavidGoh #ImperialHarvestMahjongSet #ImperialFengShui
https://imperialharvest.com/
https://www.instagram.com/imperialharvest/
The issuer is solely responsible for the content of this announcement.
About Imperial Harvest
